The Canadian Agency for Drugs and Technologies in Health (CADTH) recently sought feedback on a proposal to permit revisions to existing Canadian Drug Expert Committee (CDEC) recommendations made through the common drug review process during the therapeutic review process, eliminating the need to update recommendations through the request for advice process. The consultation period closed on August 11 2017.
During the therapeutic review process, the CDEC will consider whether any recommendations should be revised. Manufacturers will be notified at the initial therapeutic review stage of:
- any recommendation that is being revised;
- the rationale for doing so; and
- the revised reimbursement criteria and conditions.
There will be no embargo period. A formal reconsideration process will not be available, but manufacturers may provide stakeholder feedback. Their input will be considered before finalising the revised recommendations, which will occur at the meeting to finalise the therapeutic review recommendations.
For further information on this topic please contact Daphne Lainson at Smart & Biggar/Fetherstonhaugh by telephone (+1 613 232 2486) or email ([email protected]). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.